Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2523-2530

  Terui, Yasuhito ^a   Mishima, Yuji ^a   Sugimura, Natsuhiko ^a   Kojima, Kiyotsugu ^a   Sakurai, Takuma ^c   Mishima, Yuko ^a   Kuniyoshi, Ryoko ^a   Taniyama, Akiko ^a   Yokoyama, Masahiro ^a   Sakajiri, Sakura ^a   Takeuchi, Kengo ^b   Watanabe, Chie ^a   Takahashi, Shunji ^a   Ito, Yoshinori ^a   Hatake, Kiyohiko ^a,b  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c Nutritional Science Laboratory   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; CANCER RELAPSE; CARBOXY TERMINAL SEQUENCE; CD20 GENE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENE; GENE MUTATION; GENE SEQUENCE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, B-CELL; MOLECULAR SEQUENCE DATA; SEQUENCE DELETION;

EID: 65249189320     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1403     Document Type: Article

References (36)

1. Arin MJ, Hunzelmann N. Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus-an update. Eur J Dermatol 2005;15: 224-30.
2. Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 2005;12:243-53.
3. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avas- tin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-35.
4. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 2005;4: 363-74.
5. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6387-93.
6. Schmits R, Schmitz N, Pfreundschuh M. The best treatment for diffuse large B-cell lymphoma: a German perspective. Oncology (Huntingt) 2005;19:16-25.
7. Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin)in lymphoma.Ann Oncol 2005;16:786-92.
8. Haidar JH, Shamseddine A, Salem Z, et al. Loss of CD20 expression in relapsed lymphomas after rituximab therapy. Eur J Haematol 2003;70:330-2.
9. Alvaro-Naranjo T, Jaen-Martinez J, Guma-Padro J, Bosch-Princep R, Salvado-Usach MT. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Hematol 2003;82:585-8.
10. Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol 2005;32: 616-21.
11. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68.
12. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
13. Metaxa-Mariatou V, Papadopoulos S, Papadopoulou E, et al. Molecular analysis of GISTs: evaluation of sequencing and dHPLC. DNA Cell Biol 2004;23: 777 -82.
14. 14.WillmoreC, HoldenJA, Zhou L,Tripp S,WittwerCT, Layfield LJ. Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis. Am J Clin Pathol 2004; 122:206-16.
15. Bellosillo B,Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituxi- mab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001;98:2771 -7.
16. Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B- lymphoma cell lines. Leuk Res 2006;30:635 -1.
17. 17.Terui Y, Sakurai T, Mishima Y, et al. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement- dependent cytotoxicity with rituximab. Cancer Sci 2006;97:72-9.
18. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007;67:1270-81.
19. Cragg MS,Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74.
20. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol 2000;27:17-24.
21. Polyak MJ,Tailor SH, DeansJP. Identification of a cytoplasmic region of CD20 required for itsredistribution to a detergent-insoluble membrane compartment. J Immunol 1998;161:3242-8.
22. Hunter GK, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: role of glutamic acid-rich sequences in the nucleation of hydroxyap- atite by bone sialoprotein. Biochem J 1994;302: 175-9.
23. Shankar G, Gadek TR, Burdick DJ, Davison I, Mason WT, Horton MA. Structural determinants of calcium signaling by RGD peptides in rat osteoclasts: integrin-dependent and -independent actions. Exp Cell Res 1995;219:364-71.
24. DeBenedette M, Snow EC. Induction and regulation of casein kinase II during B lymphocyte activation. J Immunol 1991;147:2839-45.
25. Odegard VH, Schatz DG. Targeting of somatic hypermutation. Nat RevImmunol 2006;6:573-83.
26. Lalonde R, Strazielle C. Spontaneous and induced mouse mutations with cerebellar dysfunctions: behavior and neurochemistry. Brain Res 2007;1140: 51 -74.
27. RaggS, Xu-Welliver M, Bailey J, et al. Directreversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res 2000;60:5187-95.
28. Inoue K, Kohno T, Takakura S, Hayashi Y, Mizoguchi H, Yokota J. Frequent microsatellite instability and BAX mutations inTcell acute lymphoblastic leukemia cell lines. Leuk Res 2000;24:255-62.
29. Tomita A, Hiraga J, Kiyoi H, et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lym- phoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol 2007;86:49-57.
30. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at thepretranscrip- tional and posttranscriptional levels. Clin Cancer Res 2008;14:1561 -70.
31. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res2008;14:1550-60.
32. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
33. Sweetenham JW. Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology Am Soc Hematol Educ Program. 2005:252-9.
34. Lossos IS, Morgensztern D. Non-Hodgkin's lym- phoma in the microarray era. Clin Lymphoma 2004;5: 128-9.
35. Rossi D,Gaidano G. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis. Hematology 2002;7: 239-52.
36. Ruiz-Vela A, Piqueras R, Carvalho-Pinto C, et al. ZAP-70 upregulation in transformed B cells after early pre-BI cell transplant into NOD/SCID mice. Oncogene 2005;24:5119-24.